MSCRF Commercialization Program
Forecasted
The MSCRF Commercialization Program by TEDCO funds Maryland-based projects advancing human stem cell technologies from research toward clinical and commercial application.
Funder: Maryland Technology Development Corporation (TEDCO)
Due Dates (Anticipated): June 2027 (Application Submission Deadline, projected)
Funding Amounts: Up to $400,000 per project (12 months); up to $500,000 with Maryland research institution collaboration; total MSCRF FY27 budget: $16.05 million (across all RFAs)
Summary: Supports the advancement and commercialization of human stem cell technologies in Maryland, fostering partnerships between research institutions and businesses.
Key Information: All research activities must be conducted in Maryland; only one new PI-led application per cycle.
Description
The MSCRF Commercialization Program, administered by the Maryland Technology Development Corporation (TEDCO), accelerates the translation of human stem cell technologies with strong commercial potential toward clinical application or market readiness. The program funds therapeutic, diagnostic, and enabling technologies based on human stem cells or their derivatives, emphasizing collaborations between Maryland-based research institutions and commercial entities. Support encompasses commercialization planning, intellectual property strategy, market validation, and milestone-driven project execution, aiming to bridge the gap between scientific discovery and commercial success and to strengthen Maryland's biotechnology sector.
